
Ask a doctor about a prescription for TETRABENAZINE SUN 25 mg TABLETS
PACKAGE LEAFLET: INFORMATION FOR THE USER
Tetrabenazina SUN 25 mg tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information:
Tetrabenazina SUN belongs to a group of medicines used to treat disorders of the nervous system.
Tetrabenazina SUN is used to treat diseases that cause spasmodic, irregular, and uncontrollable movements (hyperkinetic motor disorders associated with Huntington's Chorea).
Do not take Tetrabenazina SUN
Warnings and precautions
Consult your doctor or pharmacist before starting to take Tetrabenazina SUN.
In patients treated with tetrabenazina, a drop in blood pressure may occur in certain circumstances (e.g., when standing up after being in bed). Inform your doctor if you have been told that you have low blood pressure (associated with symptoms such as dizziness, headache, tachycardia, or collapse).
Tetrabenazina and its metabolites may bind to melanin-containing tissues, where they accumulate over time. Therefore, it is possible that tetrabenazina may cause damage to these tissues with long-term use. Although there are no specific recommendations for regular eye exams, doctors who prescribe the medicine should be aware of the potential effects of long-term use of tetrabenazina on the eyes.
In clinical studies with tetrabenazina, no clinically significant changes in laboratory parameters were observed. In controlled clinical studies, tetrabenazina caused a slight increase in ALT and AST values compared to placebo.
Using Tetrabenazina SUN with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Taking other medicines
Do not use Tetrabenazina SUN with reserpine.
Treatment with monoamine oxidase inhibitors should be stopped 14 days before starting treatment with Tetrabenazina SUN, and monoamine oxidase inhibitors should not be used until at least 14 days after stopping treatment with Tetrabenazina SUN.
Tell your doctor or pharmacist before starting to use Tetrabenazina SUN with
Using Tetrabenazina SUN with alcohol
Drinking alcohol while taking Tetrabenazina SUN may make you feel unusually drowsy.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. After evaluating all the risks and benefits, your doctor will decide if you can use Tetrabenazina SUN during pregnancy.
Tetrabenazina SUN is contraindicated for breastfeeding mothers. If treatment with tetrabenazina is necessary, breastfeeding should be discontinued.
Animal studies with tetrabenazina have not shown effects on pregnancy or intrauterine survival. A prolongation of menstrual cycles was observed in females and a delay in the fertility phase.
Driving and using machines
Tetrabenazina SUN may cause drowsiness and, depending on how you respond to this treatment, your ability to drive or use machines may be affected.
Tetrabenazina SUN contains lactose. If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
Tetrabenazina SUN contains sodium. This medicine contains less than 23 mg of sodium (1mmol) per tablet; this is, essentially “sodium-free”
Follow exactly the administration instructions of this medicine given by your doctor. In case of doubt, consult your doctor or pharmacist again.
Adults
The recommended starting dose is 12.5 mg one to three times a day. This can be increased by 12.5 mg every three or four days as needed, depending on your response to treatment.
The maximum daily dose is 8 tablets of 25 mg or 16 tablets of 12.5 mg (a total of 200 mg).
If you have taken the maximum dose for a period of 7 days and your condition has not improved, it is unlikely that the medicine will provide a benefit.
Take the tablet(s) with water or another non-alcoholic drink.
Elderly
The standard dose has been administered to elderly patients without apparent adverse effects.
However, parkinsonian-like adverse effects are common.
Use in children
Treatment is not recommended in children.
Patients with hepatic disorders
Patients with mild to moderate hepatic insufficiency should start with 12.5 mg per day. Patients with severe hepatic insufficiency should be treated with caution.
Patients with renal disorders
Tetrabenazina SUN is not recommended for use in this patient group.
If you take more Tetrabenazina SUN than you should
If you take too many tablets or someone else takes your medicine by mistake,
contact your doctor or pharmacist immediately or go to the nearest hospital or call the Toxicology Information Service. Telephone 915 620 420.
The symptoms of overdose include uncontrollable muscle spasms that affect the eyes, head, neck, and body, rapid and uncontrollable eye movements, excessive blinking, nausea, vomiting, diarrhea, sweating, dizziness, feeling cold, confusion, hallucinations, drowsiness, redness/inflammation, and tremors.
If you forget to take Tetrabenazina SUN
If you forget to take a dose, do not take a double dose to make up for forgotten doses. Instead, continue with the next dose as usual.
If you stop taking Tetrabenazina SUN
Do not stop taking Tetrabenazina SUN unless your doctor tells you to. A neuroleptic malignant syndrome has been described after abrupt interruption of tetrabenazina administration (see section 4, Rare side effects).
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
More serious side effects
If you experience the following side effects, consult your doctor or go to the nearest hospital as soon as possible:
Very common (may affect more than 1 in 10 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Frequency not known (cannot be estimated from the available data)
Other side effects
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Very rare (may affect up to 1 in 10,000 people)
Frequency not known (the available data do not allow an estimate of the incidence of the following side effects)
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Pharmacovigilance System for Human Use Medicines: http://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label after the abbreviation EXP. The expiry date is the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Return the containers and any unused medicines to the pharmacy. If you are unsure, ask your pharmacist how to dispose of containers and unused medicines. This will help protect the environment.
Composition of Tetrabenazina SUN
25 mg tablets:
Appearance of the product and pack contents
Tetrabenazina SUN 25 mg tablets:
Uncoated tablet, yellow, round, flat face, beveled edge, marked with “179” on one face and scored on the other face.
Marketing authorization holder and manufacturer
Sun Pharmaceutical Industries Europe B.V.
Polarisavenue 87
2132 JH Hoofddorp
Netherlands
Local representative
Sun Pharma Laboratorios, S.L.
Rambla de Catalunya, 53-55
08007 Barcelona
Spain
Tel: +34 93 342 78 90
This medicine is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
Germany: Tetrabenazin-neuraxpharm 12.5 mg/ 25 mg Tabletten
Italy: Tetrabenazina SUN 12.5 mg/ 25 mg compresse
Netherlands: Tetrabenazine SUN 12.5 mg/ 25 mg tabletten
Spain: Tetrabenazina SUN 25 mg comprimidos EFG
United Kingdom (Northern Ireland): Tetrabenazine 12.5 mg/ 25 mg tablets
Date of last revision of this leaflet: April 2025
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of TETRABENAZINE SUN 25 mg TABLETS in October, 2025 is around 123.54 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for TETRABENAZINE SUN 25 mg TABLETS – subject to medical assessment and local rules.